Save time and jump to the most important pieces.
10-Q - MANGOCEUTICALS, INC. (0001938046) (Filer)
8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
Studies Pre-Funded, No Additional Capital Needed; Expected Completion Early Q3 2024
SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)
SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
Dallas, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that the Company received a letter on October 30, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Requirement"). As indicated in the letter, Nasdaq determined that for 10 consecutive business days, the closing bid price of the Company's common stock was at
Dallas, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value, including but not limited to potential mergers, acquisitions, divestitures and business combinations, acquisitions of businesses, entry into new lines of business, business expansions, joint ventures, and other key strategic transactions outside the ordinary course of the Company's cur
Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform learned earlier this morning that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against MangoRx claiming, that MangoRx improperly copied its weight-loss medicine, Zepbound and Mounjaro. MangoRx strongly refutes any and all claims made by Eli Lilly regarding the sale of compounded tirzepatide. MangoRx believes it has strong arguments against Eli Lilly's claims and intends to vigorously defend itself in this
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues. During the six months ending June 30, 2024, MangoRx's shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial